Market News How it works Learn FAQ
| RCT 0.0827 8.67% | NU 12.59 -16.95% | EWZ 34.15 -19.82% | BBD 2.93 -28.01% | TGL 0.2427 9.57% | AZTR 1.53 113.99% | ITUB 7.7 -20.37% | XP 15.705 -48.36% | NVD 3.99 -4.77% | SRTM 0.3 -30.28% | WFF 0.0898 12.25% | SPCX 146.9 -0.40% | PBR 22.5 -13.99% | SHFS 0.094 -29.00% | SOXL 90.5 8.31% | INTC 90.47 4.04% | VALE 12 -3.23% | NVDA 216 2.39% | CLRO 4.97 52.92% | NOK 8.64 6.14% | JBLU 2.37 -9.71% | TSLL 10.76 10.25% | CRWV 55.19 1.76% | GCDT 0.1545 -12.27% | SOXS 47.98 -8.54% | RIG 6.53 1.87% | NWGL 0.0869 5.98% | ABEV 2.83 -14.24% | RWM 14.5 -0.34% | BITO 10.65 -1.66% | AAL 12.2 0.74% | GPUS 0.1785 5.68% | TSLG 5.38 10.47% | T 20.85 -0.38% | SGRY 23.25 47.62% | IREN 25.43 2.11% | INTR 4.68 -34.91% | SBS 4.73 -26.09% | NFLX 63.9 -2.96% | GRAB 2.71 -2.87% | TSLA 391.62 5.21% | QID 14.22 -2.27% | WULF 11.98 5.83% | TQQQ 68.43 3.23% | CIFR 7.71 -2.90% | RBNE 0.17 -10.53% | SID 0.9118 -22.73% | SPDN 8.5 -0.47% | VZ 43.1 -3.49% | LUCD 0.5007 21.82%
UTMinerva Surgical, Inc. logo

Minerva Surgical, Inc. (UTRS)

Other OTC · Currency in USD
$0.00 ▲ +0.00 (+0.00%)
At close: Oct 23, 4:00 PM ET. Market closed.

Summary

Previous Close
$0.00
Open
$0.00
Day's Range
$0.00 – $0.00
52 Week Range
$0.00 – $0.00
Volume
500
Avg. Volume
1,156
Market Cap
$888
Beta (5Y Monthly)
4.60
PE Ratio (TTM)
--
EPS (TTM)
-$23.68
Earnings Date
Nov 17, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$100.00

Profile: Minerva Surgical, Inc.

Sector
Healthcare
Industry
Medical - Devices
Full-time employees
174
CEO
Darin Hammers

Minerva Surgical, Inc. functions as a commercial-stage medical technology enterprise, specializing in the creation, production, and distribution of innovative, minimally invasive solutions tailored to address the uterine healthcare needs of women throughout the United States. Their suite of offerings features advanced endometrial ablation systems, including the Minerva ES and Genesys HTA. They also provide the Symphion Tissue Removal System, a sophisticated, minimally invasive device for uterine tissue removal that uniquely integrates bladeless tissue resection, coagulation capabilities, continuous visualization during procedures, and precise intrauterine pressure monitoring.

Earnings

Next report: Tue, Nov 17, 2026
EPS estimate -$8.81 · Revenue est. $12.15M
DateEst.Actual
Nov 13, 2023-$1.00-$0.81Beat
Aug 2, 2023-$1.80-$1.00Beat
May 2, 2023-$2.20-$2.40Miss

Analyst view

Consensus price target
$100.00 ▲ +99,999,900.0%
Range $100.00 – $100.00
Rating: Buy
Buy 75% · Hold 0% · Sell 25%

Get free alerts on UTRS and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.